Celltrion Inc.’s Truxima became the first biosimilar to Roche Holding AG’s $7-billion-per-year cancer drug Rituxan to be approved in the United States to treat non-Hodgkin’s lymphoma.
Roche is investigating a case of a German patient diagnosed with a deadly brain infection called PML after taking one dose of the company’s new MS drug Ocrevus.
November 5, 2015By Mark Terry, BioSpace.com Breaking News Staff After Cambridge, Mass.-based Biogen, Inc. (BIIB) presented its research and development ambitions on Tuesday, analysts have started examining the company’s […]
PARIS – After experimental multiple sclerosis drug vatelizumab failed to meet its primary endpoints in a mid-stage trial, Sanofi AG (SNY) said it has dropped plans to develop the drug […]
Cambridge, Mass.-based Biogen, Inc. (BIIB) announced today that it was restructuring, cutting 11 percent of its workforce, and slashing programs. In addition, the company announced that its Phase III ASCEND […]
A Texas teenager who contracted a rare brain-eating disease after swimming in a lake about 70 miles (110 km) north of Houston has died, according to his family and local […]
The U.S. Food and Drug Administration said it will update the label of Novartis AG’s multiple sclerosis drug, Gilenya, after cases of serious brain infections were linked with its use. […]